viewDeepVerge PLC

Integumen PLC - Board Appointment & Admission of Shares

RNS Number : 8721X
Integumen PLC
02 May 2019

2 May 2019


Integumen PLC


("Integumen" or "Company")


Appointment of RinoCloud MD, Fionán Murray, to the Board


Admission of New Ordinary Shares


Further to the Company's announcements on 12 April 2019 and 30 April 2019, the Company confirms that Admission of the New Ordinary Shares (as defined in the 12 April 2019 announcement) took place at 8.00 a.m. this morning. Following Admission Mr Fionán Murray is confirmed as having joined the Board of Integumen as a director.


Gerard Brandon, Chief Executive Officer, commented:


"We thank our existing and new investors for their investment. Their continued support demonstrates confidence in our strategy and vision to grow Integumen into a leader in virtual microbiology testing company.  Over the last five years, Labskin has established itself as an approved supplier of products and services into a large portfolio of blue-chip skincare, pharma, personal care, wound care and health care clients across the US, EU and Asia.  Fionán Murray brings extensive expertise in the sales, innovation, collation and maintenance of secure cloud-based sensitive scientific data and his appointment underpins our commitment to deliver sustained growth and drive value for our shareholders."


Board appointment


Fionán Murray has joined Integumen as Group Sales Director, and as a Director of the Company with a focus on extending digital services on top of existing Labskin physical services to rapidly grow the Labskin AI footprint


As Managing Director of RinoCloud Fionán Murray oversaw the development of a range of software services dedicated to data management - its security, storage, curation and analysis - which generated interest from large blue-chip clients in Government, Financial Services, Healthcare and Scientific Research. Beta software deployments throughout 2017 have provided:


·      GDPR data management compliance for government;

·      Secure data collaboration between large financial services groups and their customers/distribution channels;

·      Secure data curation and collaboration for research and development groups; and

·      Big science data analysis using AI.


These existing sales, marketing and distribution channels provide the opportunity for cross selling complementary digital and physical testing services currently being rolled out as part of the Labskin AI eco-system.  This incorporates the data management and analytic services already built into Labskin AI by the RinoCloud integration.


Total Voting Rights


The issued share capital of the Company now comprises 953,173,684 Ordinary Shares with one voting right per share.  The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.


Further information in relation to Fionán Murray


Save for the information above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment Fionán Murray.


Full name:          Fionán Murray


Age:                   54 years old


Mr Murray currently holds the following directorships:


RinoCloud Limited

Small Business Base Limited (trading name: Hydrolight)

The Drive4Growth Company Limited

Monea Marketing Ltd


In the last five years, Mr Murray held the following directorships:




Mr Murray holds 86,783,068 new Ordinary Shares which represents 9.10 per cent. of the issued share capital of the Company.


Market Abuse Regulation (MAR) Disclosure


Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.




Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 643




SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Vassil Kirtchev

+44 (0) 113 370 8974




Turner Pope Investments (TPI) Limited


Andy Thacker

+44 (0) 20 3621 4120



About Integumen


Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.


The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: DeepVerge PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Market report: FTSE lacks direction and Japan's PM resigns

An up and down start for the FTSE 100 today following the news Japan's longest-serving Prime Minister has resigned due to health issues. Other main headlines today - Walmart (NYSE:WMT) has confirmed it's joining forces with Microsoft in a bid for the US assets of TikTok. It comes just...

on 08/28/2020

5 min read